Out of stock
Safety Advices
বাংলা
English
UNSAFE
Mitomycin-C may cause excessive drowsiness with alcohol.
UNSAFE
Mitomycin-C is highly unsafe to use during pregnancy. Seek your doctor's advice as studies on pregnant women and animals have shown significant harmful effects to the developing baby.
CAUTION
Mitomycin-C should be used with caution during breastfeeding. Breastfeeding should be held until the treatment of the mother is completed and the drug is eliminated from her body.
UNSAFE
Mitomycin-C may cause side effects which could affect your ability to drive.
Mitomycin-C may cause nausea and vomiting and thereby reduce your reaction times to such an extent that the ability to drive a motor vehicle is impaired.
CAUTION
Mitomycin-C should be used with caution in patients with kidney disease. Dose adjustment of Mitomycin-C may be needed. Please consult your doctor.
Use of Mitomycin-C is not recommended in patients with end-stage kidney disease.
CAUTION
Mitomycin-C should be used with caution in patients with liver disease. Dose adjustment of Mitomycin-C may be needed. Please consult your doctor.
Use of Mitomycin-C may not be recommended in some patients with liver disease.
Medicine Overview of Mitomycin-C Tablet
Introduction
Mitomycin-C is used in the treatment of certain kinds of cancer of pancreas, breast, lung, and stomach. It can be used alone or in combination with some medicines as part of combination chemotherapy. It works by interfering with the growth of cancer cells, which are eventually destroyed. Mitomycin-C is given as an injection into vein under the supervision of a doctor and should not be self-administered. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You...
... Show moreUses of Mitomycin-C
- Pancreatic cancer
- Breast cancer
- Non-small cell lung cancer
- Stomach cancer
Side effects of Mitomycin-C
Common
- Anemia (low number of red blood cells)
- Decreased white blood cell count
- Increased bleeding tendency
- Loss of appetite
- Nausea
- Vomiting
- Feeling of discomfort
- Low blood platelets
- Weight loss
- Rash
How to use Mitomycin-C
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Mitomycin-C works
Mitomycin-C is an anti-cancer medication. It works by damaging the genetic material (DNA) of the cancer cells and stops their growth and multiplication.
Quick Tips
- Inform your doctor if you have any of the following medical conditions: kidney disease; heart disease; or asthma, chronic obstructive pulmonary disease (COPD), sleep apnea, or other breathing disorder.
- Before you take mitomycin, inform your doctor if have /are being treated for kidney disease, bleeding disorder or blood disorder.
- Take precautions as mitomycin can lower the ability of your body to fight infections and the ability of your blood to clot. You may get an infection or bleed more easily.
- Seek immediate medical attention if you notice any redness, sores, oozing, or other skin changes during or after your treatment with mitomycin. Skin changes can occur several weeks or months after a mitomycin injection.
- Do not drive or operate machinery as mitomycin may cause weakness and lethargy.
- Tell your doctor if you are or planning to become pregnant or are breastfeeding.
Brief Description
Indication
Solid tumours, non-invasive bladder cancer, stomach cancer, pancreas cancer, metastatic breast cancer, advanced cervical cancer, anal carcinoma
Administration
IV Preparation
Reconstitute with SWI to a concentration of 0.5 mg/mL
IV Administration
Administer slow IV push by central line only
Flush with 5-10 mL of IV solution before & after drug administration
Adult Dose
Intravenous Solid tumours The usual dose is in the range of 4-10 mg (0.06-0.15 mg/kg) given at 1-6 weekly intervals depending on whether other drugs are given in combination and on bone marrow recovery. In a number of combination schedules, the dose is 10 mg/m2 of body surface area, the course being repeated at intervals for as long as required. A course ranging from 40-80 mg (0.58-1.2 mg/kg) is often required for a satisfactory response when used alone or in combination. A higher dosage course may be given when used alone or as part of a particular combination schedule and...
... Show moreChild Dose
Safety and efficacy not established
Renal Dose
Renal Impairment
Serum creatinine >1.7 mg/dL: Avoid use
CrCl <10 mL/min: Decrease dose by 25%
CAPD: Decrease dose by 25%
Contraindication
Hypersensitivity. Patient w/ platelet counts 1.7 mg/dL. Patient w/ substantial prolongation of prothrombin time or bleeding time, coagulation disorders, increased bleeding tendency. Pregnancy and lactation.
Mode of Action
Mitomycin is an antineoplastic antibiotic which is enzymatically reduced to its active metabolite w/in susceptible cells. The active metabolite appears to cause cross-linking of DNA (primarily w/ guanine and cytosine pairs). It is also active against gm+ve bacteria and some viruses.
Precaution
Patient w/ bone marrow depression, infections including varicella infection. Hepatic or renal impairment. Patient Counselling This drug may cause generalised weakness and lethargy, if affected, do not drive or operate machinery. Monitoring Parameters Repeated haematologic studies (platelet count, leukocyte count, differential, prothrombin time, bleeding time and Hb determinations) are necessary during therapy and for at least 7 wk following discontinuance of the drug. Carefully monitor LFTs and renal function test.
Lactation: Not known if excreted in breast milk, do not nurse
Side Effect
>10%
Hemolytic uremic syndrome (≤15%),Myelosuppression (64%),Nausea/vomiting (14%),Fever (14%)
1-10%
Stomatitis (4%),Increased serum creatinine (2%),Mucous membrane toxicity (4%)
Frequency Not Defined
Fatigue,Pulmonary toxicity,Dyspnea,Cystitis,Interstitial fibrosis,Nephrotoxicity,Amenorrhea,Alopecia
Potentially Fatal: Myelosuppression, haemolytic-uraemic syndrome.
Interaction
Increased incidence of cardiotoxicity w/ doxorubicin.
Potentially Fatal: Increased risk of intravascular haemolysis and renal failure w/ fluorouracil. Increased risk of haemolytic uraemic syndrome w/ tamoxifen. Acute pulmonary toxicity w/ vinca alkaloids (e.g. vinblastine, vinorelbine). Increased bone marrow depressant effects of aclarubicin.